How Drug-Benefi t Limits Affect Retiree Prescription Use
M
edicare's Part D standard drug benefi t has a gap in coverage-the so-called doughnut hole. At 2007 benefi t levels, coverage ends after $2,400 in pharmaceutical spending, including copays but excluding premiums, and resumes again when total drug costs reach $5,451. Between 24 and 38 percent of Medicare enrollees are expected to reach the coverage gap in 2007. As a result, many seniors with high drug expenses, especially the chronically ill, will face higher out-of-pocket costs. It is still too early to assess the eff ects of Part D, which began in 2006. However, it is possible to glimpse the likely eff ects by examining how retirees fare under private insurance plans with similar benefi t caps.
A team of RAND researchers led by Geoffrey F. Joyce used data from a private employer to examine the eff ect of benefi t caps on prescriptiondrug use by retirees. Th e data include enrollees from all 50 states and contain three years of outpatient medical and pharmacy claims (2003) (2004) (2005) . Th e employer off ered multiple prescription plans to retirees. One had a cap of $2,500 per year (similar to Part D) in plan spending. Th e employer also off ered an uncapped plan. Th e analysis compared prescription use under the capped plan with use under the uncapped plan. Th e analysis focused on enrollees with the highest prescription costs, who are most likely to be aff ected by a cap. Th is group included those spending $2,400 or more in the $2,500-cap plan. Th e researchers measured changes in drug use across seven therapeutic classes: antidepressants, antidiabetic drugs, cholesterol-lowering drugs, antihypertensives, cardiac drugs, anti-infl ammatories, and antiulcerants.
Enrollees in the Capped Plan Discontinued Drug Use at Higher Rates
Th e fi ndings showed that
• High-cost enrollees in the capped plan discontinued medication at higher rates than patients in the uncapped plan (see fi gure) across all the classes of drugs.
• Rates of discontinuation between the two plans diverged in the latter part of each year as more enrollees in the capped plan reached the limit. By December of each year, this divergence reached its highest level. Use of antihypertensives, antidepressants, antidiabetics, and cholesterol-lowering drugs was 15 to 28 percent lower among members of the capped plan. Reductions in use were even greater for the two classes of drugs with broadly available over-the-counter substitutes-anti-infl ammatories and antiulcerants.
• Th e drug classes with the greatest diff erences in discontinuation rates were antihypertensives (22 percent compared with 14 percent under the uncapped plan) and cardiac drugs (28 percent compared with 19 percent under the uncapped plan).
• Enrollees in the $2,500-cap plan also reinitiated drug use at higher rates when benefi ts resumed, suggesting that decisions to discontinue were strongly infl uenced by the benefi t limit.
Th e study also found other responses to the benefi t caps: • High-cost enrollees in capped plans stopped use of brand-name drugs at higher rates than for less-expensive, generic versions.
• High-cost enrollees who reached their spending limit in the capped plans also switched to other plans at higher rates. Th is fi nding suggests that a benefi t cap's long-term ability to contain costs is limited by the likelihood that users who encounter the ceiling will switch to a lessrestrictive plan.
Implications for Medicare Part D
Th e fi ndings suggest that prescription-benefi t limits can disrupt drug therapy for high-cost prescription users, including the chronically ill. Th is result is consistent with a growing body of evidence that higher drug-cost sharing can reduce adherence to prescriptions, leading to adverse health outcomes and subsequently higher medical costs. Of course, Medicare's drug benefi t diff ers from the study's plans in one important respect: Its benefi ts resume after spending reaches $5,451 within a calendar year. Whether this additional benefi twhich might aff ect 10 to 15 percent of the population-will result in diff erent benefi ciary responses remains unclear. Th e central policy challenge for Medicare is to motivate prescription users to spend prudently without leading them to forgo needed and cost-eff ective medication. An increasing number of plans have addressed this challenge by providing coverage for most generic drugs within the "doughnut hole"-a promising trend with little additional cost. One question about benefi t design that deserves further exploration is whether Part D could be redesigned at the same actuarial cost but with continuous coverage. For example, higher cost sharing in the form of copayments that do not vary throughout the year could result in better long-term clinical outcomes. Additional research and demonstrations would shed light on this possibility. ■ NOTE: Findings for anti-inflammatories and antiulcerants, while consistent with the patterns for other drug classes, were confounded by the widespread availability of over-the-counter alternatives and other market factors, and so are not depicted.
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